|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis显示文摘 | Xu Zhao Ying Yang Bao-Fa Sun Yue Shi Xin Yang Wen Xiao Ya-Juan Hao Xiao-Li Ping Yu-Sheng Chen Wen-Jia Wang Kang-Xuan Jin Xing Wang Chun-Min Huang Yu Fu Xiao-Meng Ge Shu-Hui Song Hyun Seok Jeong Hiroyuki Yanagisawa Yamei Niu Gui-Fang Jia Wei Wu Wei-Min Tong Akimitsu Okamoto Chuan He Jannie M Rendtlew Danielsen Xiu-Jie Wang Yun-Gui Yang | 2014 | Cell Research2014，24，12： | 109 |
| 2 | Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission显示文摘Dear Editor,The occurrence of concentrated pneumonia cases in Wuhan city,Hubei province of China was first reported on December 30,2019 by the Wuhan Municipal Health Commission(WHO,2020).The pneumonia cases were found to be linked to a large seafood and animal market in Wuhan,and measures for sanitation and disinfection were taken swiftly by the local government agency.The Centers for Disease Control and Prevention(CDC)and Chinese health authorities later determined and announced that a novel coronavirus(CoV),denoted as 2019-nCoV,had caused the pneumonia outbreak in Wuhan city(CDC,2020).Scientists from multiple groups had obtained the virus samples from hospitalized patients(Normile,2020).The isolated viruses were morphologically identical when observed under electron microscopy. | Xintian Xu Ping Chen Jingfang Wang Jiannan Feng Hui Zhou Xuan Li Wu Zhong Pei Hao | 2020 | Science China(Life Sciences)2020，63，3： | 737 |
| 3 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 4 | Prevalence of Autism Spectrum Disorder in China:A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years显示文摘This study aimed to obtain the first national estimate of the prevalence of autism spectrum disorder(ASD) in Chinese children.We targeted the population of 6 to 12-year-old children for this prevalence study by multistage convenient cluster sampling.The Modified Chinese Autism Spectrum Rating Scale was used for the screening process.Of the target population of 142,086 children,88.5%(n=125,806) participated in the study.A total of 363 children were confirmed as having ASD.The observed ASD prevalence rate was 0.29%(95% CI:0.26%-0.32%) for the overall population.After adjustment for response rates,the estimated number of ASD cases was867 in the target population sample,thereby achieving an estimated prevalence of 0.70%(95% CI:0.64%-0.74%).The prevalence was significantly higher in boys than in girls(0.95%;95% CI:0.87%-1.02% versus 0.30%;95%CI:0.26%-0.34%;P <0.001).Of the 363 confirmed ASD cases,43.3% were newly diagnosed,and most of those(90.4%) were attending regular schools,and 68.8% of the children with ASD had at least one neuropsychiatric comorbidity.Our findings provide reliable data on the estimated ASD prevalence and comorbidities in Chinese children. | Hao Zhou Xiu Xu Weili Yan Xiaobing Zou Lijie Wu Xuerong Luo Tingyu Li Yi Huang Hongyan Guan Xiang Chen Meng Mao Kun Xia Lan Zhang Erzhen Li Xiaoling Ge Lili Zhang Chunpei Li Xudong Zhang Yuanfeng Zhou Ding Ding Andy Shih Eric Fombonne Yi Zheng Jisheng Han Zhongsheng Sun Yong-hui Jiang Yi Wang LATENT-NHC Study Team | 2020 | Neuroscience Bulletin2020，36，9： | 158 |
| 5 | Towards 6G wireless communication networks:vision,enabling technologies,and new paradigm shifts显示文摘The fifth generation(5G)wireless communication networks are being deployed worldwide from 2020 and more capabilities are in the process of being standardized,such as mass connectivity,ultra-reliability,and guaranteed low latency.However,5G will not meet all requirements of the future in 2030 and beyond,and sixth generation(6G)wireless communication networks are expected to provide global coverage,enhanced spectral/energy/cost efficiency,better intelligence level and security,etc.To meet these requirements,6G networks will rely on new enabling technologies,i.e.,air interface and transmission technologies and novel network architecture,such as waveform design,multiple access,channel coding schemes,multi-antenna technologies,network slicing,cell-free architecture,and cloud/fog/edge computing.Our vision on 6G is that it will have four new paradigm shifts.First,to satisfy the requirement of global coverage,6G will not be limited to terrestrial communication networks,which will need to be complemented with non-terrestrial networks such as satellite and unmanned aerial vehicle(UAV)communication networks,thus achieving a space-airground-sea integrated communication network.Second,all spectra will be fully explored to further increase data rates and connection density,including the sub-6GHz,millimeter wave(mmWave),terahertz(THz),and optical frequency bands.Third,facing the big datasets generated by the use of extremely heterogeneous networks,diverse communication scenarios,large numbers of antennas,wide bandwidths,and new service requirements,6G networks will enable a new range of smart applications with the aid of artificial intelligence(AI)and big data technologies.Fourth,network security will have to be strengthened when developing 6G networks.This article provides a comprehensive survey of recent advances and future trends in these four aspects.Clearly,6G with additional technical requirements beyond those of 5G will enable faster and further communications to the extent that the boundary between physical and cyber worlds disappears. | Xiaohu YOU Cheng-Xiang WANG Jie HUANG Xiqi GAO Zaichen ZHANG Mao WANG Yongming HUANG Chuan ZHANG Yanxiang JIANG Jiaheng WANG Min ZHU Bin SHENG Dongming WANG Zhiwen PAN Pengcheng ZHU Yang YANG Zening LIU Ping ZHANG Xiaofeng TAO Shaoqian LI Zhi CHEN Xinying MA Chih-Lin I Shuangfeng HAN Ke LI Chengkang PAN Zhimin ZHENG Lajos HANZO Xuemin(Sherman)SHEN Yingjie Jay GUO Zhiguo DING Harald HAAS Wen TONG Peiying ZHU Ganghua YANG Jun WANG Erik GLARSSON Hien Quoc NGO Wei HONG Haiming WANG Debin HOU Jixin CHEN Zhe CHEN Zhangcheng HAO Geoffrey Ye LI Rahim TAFAZOLLI Yue GAO HVincent POOR Gerhard P.FETTWEIS Ying-Chang LIANG | 2021 | Science China(Information Sciences)2021，64，1： | 122 |
| 6 | China Stroke Statistics 2019:A Report From the National Center for Healthcare Quality Management in Neurological Diseases,China National Clinical Research Center for Neurological Diseases,the Chinese Stroke Association,National Center for Chronic and Non-communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations显示文摘China faces the greatest challenge from stroke in the world.The death rate for cerebrovascular diseases in China was 149.49 per 100000,accounting for 1.57 million deaths in 2018.It ranked third among the leading causes of death behind malignant tumours and heart disease.The age-standardised prevalence and incidence of stroke in 2013 were 1114.8 per 100000 population and 246.8 per 100000 person-years,respectively.According to the Global Burden of Disease Study 2017,the years of life lost(YLLs)per 100000 population for stroke increased by 14.6%;YLLs due to stroke rose from third highest among all causes in 1990 to the highest in 2017.The absolute numbers and rates per 100000 population for all-age disability-adjusted life years(DALYs)for stroke increased substantially between 1990 and 2017,and stroke was the leading cause of all-age DALYs in 2017.The main contributors to cerebrovascular diseases include behavioural risk factors(smoking and alcohol use)and pre-existing conditions(hypertension,diabetes mellitus,dyslipidaemia and atrial fibrillation(AF)).The most prevalent risk factors among stroke survivors were hypertension(63.0%-84.2%)and smoking(31.7%-47.6%).The least prevalent was AF(2.7%-7.4%).The prevalences for major risk factors for stroke are high and most have increased over time.Based on the latest national epidemiological data,26.6%of adults aged≥15 years(307.6 million adults)smoked tobacco products.For those aged≥18 years,age-adjusted prevalence of hypertension was 25.2%;adjusted prevalence of hypercholesterolaemia was 5.8%;and the standardised prevalence of diabetes was 10.9%.For those aged≥40 years,the standardised prevalence of AF was 2.31%.Data from the Hospital Quality Monitoring System showed that 3010204 inpatients with stroke were admitted to 1853 tertiary care hospitals during 2018.Of those,2466785(81.9%)were ischaemic strokes(ISs);447609(14.9%)were intracerebral haemorrhages(ICHs);and 95810(3.2%)were subarachnoid haemorrhages(SAHs).The average age of patients admitted was 66 years old,and nearly 60%were male.A total of 1555(0.1%),2774(0.6%)and 1347(1.4%)paediatric strokes(age<18 years)were identified among IS,ICH and SAH,respectively.Over one-third(1063892(35.3%))of the patients were covered by urban resident basic medical insurance,followed by urban employee basic medical insurance(699513(23.2%))and new rural cooperative medical schema(489361(16.3%)).The leading risk factor was hypertension(67.4%for IS,77.2%for ICH and 49.1%for SAH),and the leading comorbidity was pneumonia or pulmonary infection(10.1%for IS,31.4%for ICH and 25.2%for SAH).In-hospital death/discharge against medical advice rate was 8.3%for stroke inpatients,ranging from 5.8%for IS to 19.5%for ICH.The median and IQR of length of stay was 10.0(7.0-14.0)days,ranging from 10.0(7.0-13.0)in IS to 14.0(8.0-22.0)in SAH.Data from the Chinese Stroke Center Alliance demonstrated that the composite scores of guideline-recommended key performance indicators for patients with IS,ICH and SAH were 0.77±0.21,0.72±0.28 and 0.59±0.32,respectively. | Yong-Jun Wang Zi-Xiao Li Hong-Qiu Gu Yi Zhai Yong Jiang Xing-Quan Zhao Yi-Long Wang Xin Yang Chun-Juan Wang Xia Meng Hao Li Li-Ping Liu Jing Jing Jing Wu An-Ding Xu Qiang Dong David Wang Ji-Zong Zhao On behalf of China Stroke Statistics 2019 Writing Committee | 2020 | Stroke & Vascular Neurology2020，5，3： | 181 |
| 7 | The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer显示文摘China is one of the countries with the highest incidence of gastric cancer.There are differences in epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selection between gastric cancer patients from the Eastern and Western countries.Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients.The Chinese Society of Clinical Oncology(CSCO)arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile,discuss,and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad.By referring to the opinions of industry experts,taking into account of regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted experts’consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes.This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis,comprehensive treatment,and follow-up visits for gastric cancer. | Feng-Hua Wang Lin Shen Jin Li Zhi-Wei Zhou Han Liang Xiao-Tian Zhang Lei Tang Yan Xin Jing Jin Yu-Jing Zhang Xiang-Lin Yuan Tian-Shu Liu Guo-Xin Li Qi Wu Hui-Mian Xu Jia-Fu Ji Yuan-Fang Li Xin Wang Shan Yu Hao Liu Wen-Long Guan Rui-Hua Xu | 2019 | Cancer Communications2019，39，1： | 127 |
| 8 | The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021显示文摘There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western countries.The Chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually.Taking into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China.The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric cancer.Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from China and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations.For the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant treatment.The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated.For the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided. | Feng-Hua Wang Xiao-Tian Zhang Yuan-Fang Li Lei Tang Xiu-Juan Qu Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi Xiang-Lin Yuan Sheng-Xiang Rao Yan Xin Wei-Qi Sheng Hui-Mian Xu Guo-Xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang Yan-Qiao Zhang Jing Jin Lin Shen Jin Li Rui-Hua Xu | 2021 | Cancer Communications2021，41，8： | 97 |
| 9 | Long-term monitoring and source apportionment of PM_(2.5)/PM_(10) in Beijing,China显示文摘During 2001-2006,PM2.5 (particle matter with aerodynamic diameter less than 2.5 microns) and PM10 (particle matter with aerodynamic diameter less than 10 microns) were collected at the Beijng Normal University (BNU) site,China,and in 2006,at a background site in Duolun (DL).The long-term monitoring data of elements,ions,and black carbon showed that the major constituents of PM2.5 were black carbon (BC) crustal elements,nitrates,ammonium salts,and sulfates.These five major components accounted for 20%-80% of the total PM2.5.During this period,levels of Pb and S in PM remained rather high,as compared with the levels in other large cities in the world.Source apportionment results suggest that there were 6 common sources for PM2.5 and PM10,i.e.,soil dust,vehicular emission,coal combustion,secondary aerosol,industrial emission,and biomass burning.Coal combustion was the largest contributor of PM2.5 with a percentage of 16.6%,whereas soil dust played the most important role in PM10 with a percentage of 27%.In contrast,only three common types of sources could be resolved at the background DL site,namely,soil dust,biomass combustion,and secondary aerosol from combustion sources. | Hailin WANG Zhengping HAO | 2008 | Journal of Environmental Sciences2008，20，11： | 65 |
| 10 | Surveillance of Hand,Foot,and Mouth Disease in China's Mainland (2008-2009)显示文摘Objective Since HFMD was designated as a class C communicable disease in May 2008,18 months surveillance data have been accumulated to December 2009.This article was to describe the distribution of HFMD for age,sex,area,and time between 2008 and 2009,to reveal the characteristics of the epidemic.Methods We analyzed weekly reported cases of HFMD from May 2008 to December 2009,and presented data on the distribution of age,sex,area and time.A discrete Poisson model was used to detect spatial-temporal clusters of HFMD.Results More than 1 065 000 cases of HFMD were reported in China's Mainland from May 2008 to December 2009 (total incidence:12.47 per 10 000).Male incidence was higher than female for all ages and 91.9% of patients were <5 years old.The incidence was highest in Beijing,Shanghai,Zhejiang and Hainan.The highest peak of HFMD cases was in April and the number of cases remained high from April to August.The spatial-temporal distribution detected four clusters.Conclusion Children <5 years old were susceptible to HFMD and we should be aware of their vulnerability.The incidence was higher in urban than rural areas,and an annual pandemic usually starts in April. | ZHU Qi HAO YuanTao MA JiaQi YU ShiCheng WANG Yu | 2011 | Biomedical and Environmental Sciences2011，24，4： | 73 |
| 11 | Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21^(WAF1) expression and hepatic apoptosis显示文摘AIM To detect the expression of caspase 3gene in primary human hepatocellular carcinoma(HCC)and investigate its relationship to p21WAF1gene expression and HCC apoptosis.METHODS In situ hybridization was employedto determine caspase 3 and p21WAF1expression inHCC.In situ end-labeling was used to detecthepatocytic apoptosis in HCC.RESULTS Twenty-one of 39(53.8%)cases ofHCC were found to express caspase 3transcripts,while 45.2% of HCC failed toexpress caspase 3.Non-cancerous adjacent livertissues showed more positive caspase 3(87.5%,7/8)as compared with HCC(P<0.05).The expression of caspase 3 is correlated withHCC differentiation,72.2%(13/18)ofmoderately to highly differentiated HCC showedcaspase 3 transcripts positive,while only 38.1%of poorly differentiated HCC harbored caspase 3transcripts(P<0.05).No relationship wasfound between caspase 3 expression and tumorsize or grade or metastasis,although 52.5%(5/8)of HCC with metastasis were caspase 3positive and a little higher than that with nometastasis(51.6%,P>0.05).Expression of caspase 3 alone did not affect the apoptosisindex(AI)of HCC.The AI was 7.12%o in caspase3-positive tumors(n=21),while in caspase 3-negative cases(n=18)6.59%0(P>0.05).Expression of caspase 3 clearly segregated withp21WAF1positive tumors as compared withp21WAF1-negative cases(16 of 23,69.6% versus5 of 16,31.3%)with statistical significance(P=0.017).In the cases with positive caspase 3and negative p21WAF1,the Al was found slightlyhigher,but with no statistical significance,thanthat with expression of p21WAF1and caspase 3(7.21‰ vs 6.98‰,P>0.05).CONCLUSION Loss of caspase 3 expressionmay contribute to HCC carcinogenesis,althoughthe expression of caspase 3 does not correlatewell with cell apoptosis in HCC.p21WAF1may bemerely one of the inhibitors which can reducecaspase 3 mediated cell apoptosis in HCCs. | Bao Hua Sun Jun Zhang Bao JǜWang Xi Ping Zhao You Kun Wang Zhi Qun Yu Dong Liang Yang Lian Jie Hao Department of Clinical Immunology,Tongji Hospital,Tongji Medical University,Wuhan 430030,Hubei Province,China | 2000 | World Journal of Gastroenterology2000，6，3： | 65 |
| 12 | Air quality management in China:Issues,challenges,and options显示文摘This article analyzed the control progress and current status of air quality,identified the major air pollution issues and challenges in future,proposed the long-term air pollution control targets,and suggested the options for better air quality in China.With the continuing growth of economy in the next 10-15 years,China will face a more severe situation of energy consumption,electricity generation and vehicle population leading to increase in multiple pollutant emissions.Controlling regional air pollution especially fine particles and ozone,as well as lowering carbon emissions from fossil fuel consumption will be a big challenge for the country.To protect public health and the eco-system,the ambient air quality in all Chinese cities shall attain the national ambient air quality standards (NAAQS) and ambient air quality guideline values set by the World Health Organization (WHO).To achieve the air quality targets,the emissions of SO 2,NOx,PM 10,and volatile organic compounds (VOC) should decrease by 60%,40%,50%,and 40%,respectively,on the basis of that in 2005.A comprehensive control policy focusing on multiple pollutants and emission sources at both the local and regional levels was proposed to mitigate the regional air pollution issue in China.The options include development of clean energy resources,promotion of clean and efficient coal use,enhancement of vehicle pollution control,implementation of synchronous control of multiple pollutants including SO 2,NOx,VOC,and PM emissions,joint prevention and control of regional air pollution,and application of climate friendly air pollution control measures. | Shuxiao Wang Jiming Hao | 2012 | Journal of Environmental Sciences2012，24，1： | 71 |
| 13 | Size distributions and sources of elements in particulate matter at curbside,urban and rural sites in Beijing显示文摘Size distributions of 29 elements in aerosols collected at urban,rural and curbside sites in Beijing were studied.High levels of Mn,Ni,As,Cd and Pb indicate the pollution of toxic heavy metals cannot be neglected in Beijing.Principal component analysis (PCA) indicates 4 sources of combustion emission,crust related sources,traffic related sources and volatile species from coal combustion.The elements can be roughly divided into 3 groups by size distribution and enrichment factors method (EFs).Group 1 elements are crust related and mainly found within coarse mode including Al,Mg,Ca,Sc,Ti,Fe,Sr,Zr and Ba;Group 2 elements are fossil fuel related and mostly concentrated in accumulation mode including S,As,Se,Ag,Cd,Tl and Pb;Group 3 elements are multi-source related and show multi-mode distribution including Be,Na,K,Cr,Mn,Co,Ni,Cu,Zn,Ga,Mo,Sn and Sb.The EFs of Be,S,Cr,Co,Ni,Cu,Ga,Se,Mo,Ag,Cd,Sb,Tl and Pb show higher values in winter than in summer indicating sources of coal combustion for heating in winter.The abundance of Cu and Sb in coarse mode is about 2-6 times higher at curbside site than at urban site indicating their traffic sources.Coal burning may be the major source of Pb in Beijing since the phase out of leaded gasoline,as the EFs of Pb are comparable at both urban and curbside sites,and about two times higher in winter than that in summer. | Jingchun Duan Jihua Tan Shulan Wang Jimin Hao Fahe Chai | 2012 | Journal of Environmental Sciences2012，24，1： | 67 |
| 14 | 5-methylcytosine promotes mRNA export--NSUN2 as the methyltransferase and ALYREF as an m5C reader显示文摘 | Yang, Xin Yang, Ying Sun, Bao-Fa Chen, Yu-Sheng Xu, Jia-Wei Lai, Wei-Yi Li, Ang Wang, Xing Bhattarai, Devi Prasad Xiao, Wen Sun, Hui-Ying Zhu, Qin Ma, Hai-Li Adhikari, Samir Sun, Min Hao, Ya-Juan Zhang, Bing Huang, Chun-Min Huang, Niu Jiang, Gui-Bin Zhao, Yong-Liang Wang, Hai-Lin Sun, Ying-Pu Yang, Yun-Gui | 2017 | Cell Research2017，27，5： | 62 |
| 15 | Wnt/b-catenin signaling plays an ever-expanding role in stem cell self-renewal,tumorigenesis and cancer chemoresistance显示文摘Wnt signaling transduces evolutionarily conserved pathways which play important roles in initiating and regulating a diverse range of cellular activities,including cell proliferation,calcium homeostasis,and cell polarity.The role of Wnt signaling in controlling cell proliferation and stem cell self-renewal is primarily carried out through the canonical pathway,which is the best-characterized the multiple Wnt signaling branches.The past 10 years has seen a rapid expansion in our understanding of the complexity of this pathway,as many new components of Wnt signaling have been identified and linked to signaling regulation,stem cell functions,and adult tissue homeostasis.Additionally,a substantial body of evidence links Wnt signaling to tumorigenesis of cancer types and implicates it in the development of cancer drug resistance.Thus,a better understanding of the mechanisms by which dysregulation of Wnt signaling precedes the development and progression of human cancer may hasten the development of pathway inhibitors to augment current therapy.This review summarizes and synthesizes our current knowledge of the canonical Wnt pathway in development and disease.We begin with an overview of the components of the canonical Wnt signaling pathway and delve into the role this pathway has been shown to play in stemness,tumorigenesis,and cancer drug resistance.Ultimately,we hope to present an organized collection of evidence implicating Wnt signaling in tumorigenesis and chemoresistance to facilitate the pursuit of Wnt pathway modulators that may improve outcomes of cancers in which Wnt signaling contributes to aggressive disease and/or treatment resistance. | Maryam K.Mohammed Connie Shao Jing Wang Qiang Wei Xin Wang Zachary Collier Shengli Tang Hao Liu Fugui Zhang Jiayi Huang Dan Guo Minpeng Lu Feng Liu Jianxiang Liu Chao Ma Lewis L.Shi Aravind Athiviraham Tong-Chuan He Michael J.Lee | 2016 | Genes & Diseases2016，3，1： | 70 |
| 16 | Artificial intelligence in healthcare:past,present and future显示文摘Artificial intelligence(AI)aims to mimic human cognitive functions.It is bringing a paradigm shift to healthcare,powered by increasing availability of healthcare data and rapid progress of analytics techniques.We survey the current status of AI applications in healthcare and discuss its future.AI can be applied to various types of healthcare data(structured and unstructured).Popular AI techniques include machine learning methods for structured data,such as the classical support vector machine and neural network,and the modern deep learning,as well as natural language processing for unstructured data.Major disease areas that use AI tools include cancer,neurology and cardiology.We then review in more details the AI applications in stroke,in the three major areas of early detection and diagnosis,treatment,as well as outcome prediction and prognosis evaluation.We conclude with discussion about pioneer AI systems,such as IBM Watson,and hurdles for real-life deployment of AI. | Fei Jiang Yong Jiang Hui Zhi Yi Dong Hao Li Sufeng Ma Yilong Wang Qiang Dong Haipeng Shen Yongjun Wang | 2017 | Stroke & Vascular Neurology2017，2，4： | 76 |
| 17 | 高血压病中医分型的代谢组学研究(英文)显示文摘目的:将传统中医辨证方法同现代系统生物学理论相结合,探讨原发性高血压辨证分型与基于GC/MS的血清代谢组学的关系。方法:原发性高血压辨证分为肝火亢盛、痰湿雍盛及阴虚阳亢三型。应用GC/MS测定健康人及原发性高血压病人血清内源性代谢物,并用主成分分析(PCA)、偏最小乘方分析(PLS-DA)和马氏距离(MD)分析他们的代谢谱。结果:PCA和PLS-DA分析的结果表明:健康人与高血压病人血清代谢谱有明显差异,能够被区分开,但PCA和PLS-DA不能将中医高血压的三型完全分开。利用MD不仅可以清晰地区分上述三种类型的高血压,同时还显示高血压的发展过程。结论:基于GC/MS和模式识别的代谢组学在揭示传统中医理论本质上有着广泛的应用前景。 | LU Yi-hong HAO Hai-ping WANG Guang-ji CHEN Hu-xiao ZHU Xuan-xuan XIANG Bing-ren HUANG Qing A Ji-Y | 2007 | 中国临床药理学与治疗学2007，12，10： | 54 |
| 18 | Improved quality of life in patients with gastric cancer after esophagogastrostomy reconstruction显示文摘AIM:To compare postoperative quality of life (QOL) in patients with gastric cancer treated by esophagogastrostomy reconstruction after proximal gastrectomy.METHODS: QOL assessments that included functional outcomes (a 24-item survey about treatment-specific symptoms) and health perception (Spitzer QOL Index) were performed in 149 patients with gastric cancer in the upper third of the stomach, who had received proximal gastrectomy with additional esophagogastrostomy.RESULTS: Fifty-four patients underwent reconstruction by esophagogastric anterior wall end-to-side anastomosis combined with pyloroplasty (EA group); 45 patients had reconstruction by esophagogastric posterior wall end-to-side anastomosis (EP group); and 50 patients had reconstruction by esophagogastric end-to-end anastomosis (EE group). The EA group showed the best postoperative QOL, such as recovery of body weight, less discomfort after meals, and less heart burn or belching at 6 and 24 mo postoperatively. However, the survival rates, surgical results and Spitzer QOL index were similar among the three groups.CONCLUSION: Postoperative QOL was better in the EA than EP or EE group. To improve QOL after proximal gastrectomy for upper third gastric cancer, the EA procedure using a stapler is safe and feasible for esophagogastrostomy. | Hao Zhang Zhe Sun Hui-Mian Xu Ji-Xian Shan Shu-Bao Wang Jun-Qing Chen | 2009 | World Journal of Gastroenterology2009，15，25： | 54 |
| 19 | Characterization and assessment of volatile organic compounds (VOCs) emissions from typical industries显示文摘VOCs play an increasingly important role in affecting air quality and threatening human health in China in recent years,where industry activities show a significant contribution to VOCs emission.In this article we report our long term study of industrial VOCs emissions of six major industries (vehicle manufacturing,printing,equipment coating,electronic manufacturing,furniture manufacturing and bio-pharming) on the aspects of emission characteristics,environmental impact and health risk assessment,and control challenge analysis with the purpose to obtain in-depth understanding of industry VOCs emissions and offer some original basements for national control and management of industry VOCs emissions.This study shows that all these industries give middle or low emission with total VOCs concentration less than 1000 mg/m3 at each exhaust pipe.Benzenes,esters,alcohols,ketones,alkanes,chloroalkanes and alkenes were detected as the major emission components and the most frequently monitored VOCs were benzenes,which varied obviously with different processes and industries.The environmental impact assessments indicate that vehicle manufacturing and benzenes should be prior controlled with the purpose to reduce air pollution.While,health risk assessments suggest that furniture manufacturing and chloroalkanes should be firstly controlled.Control analysis indicates that developing technologies with low cost and high efficiency and establishing and completing specific industry emission standards/regulations are the two key issues in VOCs emission management at present stage. | WANG HaiLin NIE Lie LI Jing WANG YuFei WANG Gang WANG JunHui HAO ZhengPing | 2013 | Science China(Technological Sciences)2013，56，3： | 60 |
| 20 | Efficacy of cattle encephalon glycoside and ignotin in patients with acute cerebral infarction: a randomized, double-blind, parallel-group, placebo-controlled study显示文摘Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a safe and effective treatment for acute cerebral infarction patients,especially for moderate stroke patients.This study was approved by the Ethical Committee of Peking University Third Hospital,China(approval No.2013-068-2)on May 20,2013,and registered in the Chinese Clinical Trial Registry(registration No.ChiCTR1800017937). | Hui Zhang Chuan-Ling Li Feng Wan Su-Juan Wang Xiu-E Wei Yan-Lei Hao Hui-Lin Leng Jia-Min Li Zhong-Rui Yan Bao-Jun Wang Ren-Shi Xu Ting-Min Yu Li-Chun Zhou Dong-Sheng Fan | 2020 | Neural Regeneration Research2020，15，7： | 54 |
您所在的机构暂未开通此部分的功能，请联系管理员